At 11.9% CAGR, the Asia Pacific Intradermal Injection Market is projected to be worth US$ 1,698.43 million by 2028, says Business Market Insights         

According to the Insight Partners’ research, the Asia Pacific intradermal injection market was valued at US$ 774.05 million in 2021 and is expected to reach US$ 1,698.43 million by 2028, registering an annual growth rate of 11.9% from 2021 to 2028.Significant growth opportunities in developed as well as developing countries and strategic developments by manufacturers are the critical factors attributed to the market expansion.                

Manufacturers in the Asia Pacific Intradermal Injection market are adopting developmental strategies such as partnerships, collaborations, product launches, approvals, and mergers and acquisitions to sustain the competitive environment in the market. The companies are also undertaking the partnerships activities to strengthen their presence in the market and to boost the clinical research work for speeding up the development of various new candidates. The medical equipment manufacturers across the world are scaling up the production of their devices. Their involvement in various business developments and product innovations helps ensure the easy availability of the products in the regional markets. Moreover, the regulatory agencies are providing the required support through timely product approvals and permissions. Such strategic activities by manufacturers are expected to propel the growth of the ASIA PACIFIC intradermal injection market in coming years.  

On the contrary, risks, complications, and dosing limitations associated with intradermal injections hurdles the growth of Asia Pacific intradermal injection market. 

• Based on method, the Asia Pacific intradermal injection market is segmented into normal sized needles, short needle, and without needle. The normal sized needles segment held 41.7% market share in 2021, amassing US$ 322.77 million. It is projected to garner US$ 683.12 million by 2028 to expand at 11.3% CAGR during 2021–2028. The normal sized needles segment is further subsegmented into intradermal microinjection, microneedle arrays, and tattoo devices. The short needle segment is further subsegmented intradermal liquid jet injectors and ballistic intradermal injectors.
• Based on application, the Asia Pacific intradermal injection market is segmented into tuberculin skin test, allergy test, local aesthetics, and others. The tuberculin skin test segment held 30.2% market share in 2021, amassing US$ 234.03 million. It is projected to garner US$ 505.49 million by 2028 to expand at 11.6% CAGR during 2021–2028.
• Based on end user, the Asia Pacific intradermal injection market is segmented into hospitals, diagnostic laboratories, academics and research institutes, and others. The hospitals segment held 39.7% market share in 2021, amassing US$ 306.99 million. It is projected to garner US$ 679.74 million by 2028 to expand at 12.0% CAGR during 2021–2028.
• Based on country, the Asia Pacific intradermal injection market has been categorized into Australia, China, India, Japan, South Korea, and rest of APAC.  Our regional analysis states that China captured 39.4% market share in 2021. It was assessed at US$ 304.65 million in 2021 and is likely to hit US$ 676.73 million by 2028, exhibiting a CAGR of 12.1% during the forecast period.  

Key players profiles in the Asia Pacific intradermal injection market report are BD; West Pharmaceutical Services, Inc; Terumo Corporation; Nanopass; PharmaJet; Idevax; Eunsung Global; Crossject; Cardinal Health Inc; and Hindustan Syringes and Medical Devices Ltd among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com